Merck and Gilead report mixed outcomes in lung cancer and HIV studies

Merck and Gilead Report Mixed Outcomes in Lung Cancer and HIV Studies

Key Takeaways

• Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant improvement in progression-free survival, though the data showed a numerical benefit.
• Gilead and Merck reported positive topline results from two Phase 3 studies evaluating Islatravir/Lenacapavir as an oral once-weekly HIV treatment.
• The halted lung cancer trial does not affect Trodelvy's current FDA-approved indication in triple-negative breast cancer.
• Investors and analysts should await fuller data disclosure and any updated development plans from both companies.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for HIV, with Trodelvy and KEYTRUDA most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

The Lung Cancer Trial Halt and HIV Progress in Context

Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant improvement in progression-free survival. The trial did not reach its primary endpoint, though a numerical improvement was observed.

In parallel, Gilead and Merck reported positive topline results from two Phase 3 studies evaluating Islatravir/Lenacapavir as an oral once-weekly HIV treatment. The positive HIV data represents a different clinical trajectory from the oncology setback, underscoring the divergent performance across the two companies' shared pipeline.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Merck & Co. and Gilead Sciences reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Regulatory Status and Current Approved Uses

TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies. This breast cancer indication remains unaffected by the halted lung cancer trial.

KEYTRUDA QLEX is indicated in combination with pemetrexed and platinum chemotherapy as first-line treatment of adult patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for HIV. Expect implications for pricing, access, and launch sequencing.

Pipeline Catalysts in Oncology Remain Active

Despite the halted lung cancer combination study, Trodelvy continues to be evaluated across multiple indications in active development. A Phase 3 study (NCT05633654) is recruiting patients to compare sacituzumab govitecan and pembrolizumab versus physician's choice treatment in triple-negative breast cancer with residual invasive disease after surgery and neoadjuvant therapy. A Phase 3 neoadjuvant trial (NCT07178730) is not yet recruiting, comparing sacituzumab govitecan plus pembrolizumab to standard-of-care chemotherapy in clinical stage II–III triple-negative early breast cancer.

The Trodelvy-pembrolizumab combination is also under investigation in other solid tumors. A Phase 2 study (NCT07504588) is not yet recruiting, evaluating sacituzumab govitecan with bevacizumab compared to standard chemotherapy in recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance. A Phase 3 trial (NCT06524544) is recruiting to compare pembrolizumab and sacituzumab govitecan versus standard of care in advanced urothelial cancer.

IntelligenceStrategic Takeaways▾

Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant improvement in progression-free survival , though the data showed a numerical benefit. Gilead and Merck reported positive topline results from two Phase 3 studies evaluating Islatravir/Lenacapavir as an oral once-weekly HIV treatment. The halted lung cancer trial does not affect Tro

What the Mixed Readout Means for Pharma Teams

The divergent outcomes separate near-term clinical momentum in HIV from a lung cancer setback in combination oncology. The lung cancer trial halt provides a specific data point on the Trodelvy-KEYTRUDA combination's efficacy in that indication, while the positive HIV topline results offer a contrasting clinical signal for the islatravir/lenacapavir regimen. For investors and analysts, the importance of awaiting fuller disclosure and any updated development plans before drawing conclusions about the full scope of each program's trajectory remains clear.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source.

What to Watch Next

Investors and analysts should monitor for fuller data release on the halted lung cancer trial, development decisions for the Trodelvy combination program, and next-step updates on the regulatory pathway for the once-weekly islatravir/lenacapavir HIV regimen.

Frequently Asked Questions

Related profiles

• Gilead Sciences
• TRODELVY
• KEYTRUDA
• lenacapavir

Related coverage

• EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
• EMA backs datopotamab deruxtecan for advanced lung cancer
• Digital Money report summary: monetary architecture, CBDC, stablecoins and regulation